source
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpointMerck and Moderna reported that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence in a Phase 3 study. The interim analysis showed a statistically si…
- Merck and Moderna report personalized mRNA vaccine delays melanoma recurrence in late-stage trialMerck and Moderna announced that a personalized mRNA cancer vaccine, when combined with standard therapy, slowed the return of melanoma and reduced its spread in a late-stage clinical study. The tr…